What is AM-Pharma?
Founded in 2001, AM-Pharma operates at the intersection of advanced pharmaceutical manufacturing and clinical research. The company is primarily focused on developing novel therapeutic interventions for acute kidney injury, a condition that presents significant challenges in critical care settings. By maintaining a rigorous focus on late-stage clinical development, AM-Pharma has established itself as a pivotal player in the European biotech ecosystem, bridging the gap between academic discovery and commercial-grade medical solutions. Its operational model relies on deep scientific expertise and a strategic approach to drug development that targets high-unmet medical needs.
How much funding has AM-Pharma raised?
AM-Pharma has raised a total of $325.2M across 6 funding rounds:
Series A
$781K
Series C
$3M
Series D
$34.5M
Series E
$14.4M
Private Equity
$87.5M
Series F
$185M
Series A (2001): $781K with participation from Biopartners Capital
Series C (2007): $3.1M led by Inventages and Forbion Capital
Series D (2011): $34.5M supported by Idinvest Partners, Inventages, Forbion, Kurma Partners, BB Biotech Ventures, and Ysios Capital Partners
Series E (2014): $14.4M featuring IDInvest Partners, Gilde Healthcare, Ysios Capital, AbbVie, BB Biotech Ventures, and Kuma Biofund
Private Equity (2015): $87.5M backed by Pfizer
Series F (2020): $185M with participation from Ysios Capital, Kurma Partners, Life Sciences Partners, BB Pureos Bioventures, ID Invest Partners, Gilde Healthcare, Andera Partners, Cowen Healthcare Investments, and European Investment Bank
Key Investors in AM-Pharma
Ysios Capital
A leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, focusing on novel therapies for high unmet medical needs.
Gilde Healthcare
A specialized healthcare investment firm managing over 1.4 billion euros across strategies including venture and growth, private equity, and climate solutions.
Kurma Partners
A prominent European player in financing healthcare and biotechnology ventures, specializing in transforming disruptive scientific discoveries into advanced medical solutions.
What's next for AM-Pharma?
Following the recent capital injection, AM-Pharma is well-positioned to accelerate its late-stage clinical trials and refine its manufacturing capabilities. The firm's strategic roadmap likely involves scaling its therapeutic pipeline and preparing for potential regulatory milestones. By leveraging the backing of specialized life sciences investors, the company is poised to transition from a development-focused entity toward a more integrated commercial presence. Future growth will likely be defined by the successful completion of ongoing clinical programs and the potential for further strategic partnerships within the global biopharmaceutical landscape.
See full AM-Pharma company page
